Antidepressant pharmacogenetics

American Journal of Psychiatry

Volumn 174, Issue 5, 2017, Pages 417-418

  Singh, Ajeet B ^a,b   Bousman, Chad A ^a,b  

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; NORADRENALIN TRANSPORTER; VENLAFAXINE;

ADVERSE OUTCOME; EDITORIAL; ENVIRONMENTAL FACTOR; EPIGENETICS; EVIDENCE BASED MEDICINE; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GOLD STANDARD; HUMAN; MAJOR DEPRESSION; NOREPINEPHRINE TRANSPORTER GENE; PHARMACOGENETICS; PRACTICE GUIDELINE; PREDICTION; PRESCRIPTION; REMISSION; RISK BENEFIT ANALYSIS; RISK FACTOR; SYMPTOM; TREATMENT RESPONSE; DEPRESSION;

ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; PHARMACOGENETICS;

EID: 85018422421     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2017.17020173     Document Type: Editorial

References (14)

1. Marshe VS, Maciukiewicz M, Rej S, et al: Norepinephrine transporter gene variants and remission from depression with venlafaxine treatment in older adults. Am J Psychiatry 2017; 174: 468-475
2. Murray CJL, Vos T, Lozano R, et al: Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2197-2223
3. Whyte EM, Basinski J, Farhi P, et al: Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors. J Clin Psychiatry 2004; 65:1634-1641
4. Rosenblat JD, Lee Y, McIntyre RS: Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost-effectiveness studies. J Clin Psychiatry (Epub ahead of print, Jan 3, 2017)
5. Singh AB, Bousman CA, Ng C, et al: Antidepressant pharmacogenetics. Curr Opin Psychiatry 2014; 27:43-51
6. Bousman CA, Hopwood M: Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry 2016; 3: 585-590
7. Malhi GS, Bassett D, Boyce P, et al: Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015; 49:1087-1106
8. Kennedy SH, Lam RW, McIntyre RS, et al: Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3: Pharmacological Treatments. Can J Psychiatry 2016; 61: 540-560
9. Hicks JK, Bishop JR, Sangkuhl K, et al: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther 2015; 98: 127-134
10. US Food and Drug Administration: Table of Pharmacogenomic Biomarkers inDrugLabeling. http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm
11. Winner JG, Carhart JM, Altar CA, et al: A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. DiscovMed 2013; 16:219-227
12. Singh AB: Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report. Clin Psychopharmacol Neurosci 2015; 13:150-156
13. Pérez V, Espadaler J, Tuson M, et al: Effectiveness of pharmacogenetic information in the treatment of major depressive disorder: results from the AB-GEN randomized clinical trial. Programme of the 29th European College of Neuropsychopharmacology Congress, Vienna, 2016. Poster ECNP P2.b.044
14. Hamann J, Kohl S, McCabe R, et al: What can patients do to facilitate shared decision making? A qualitative study of patients with depression or schizophrenia and psychiatrists. Soc Psychiatry Psychiatr Epidemiol 2016; 51:617-625